Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Dual specificity protein kinase CLK2 | ||
Ligand | BDBM317482 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | Radioactivity Based Kinase Assay | ||
IC50 | 1.43±n/a nM | ||
Citation | Zhu, D; Boylan, J; Xu, S; Riggs, J; Shi, T; Wurmser, A; Mikolon, D; Deyanat-Yazdi, G Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof US Patent US9623028 Publication Date 4/18/2017 | ||
More Info.: | Get all data from this article, Assay Method | ||
Dual specificity protein kinase CLK2 | |||
Name: | Dual specificity protein kinase CLK2 | ||
Synonyms: | 2.7.12.1 | CDC-like kinase 2 | CDC-like kinase 2 (CLK2) | CDC2-like kinase 2 (CLK2) | CLK2 | CLK2_HUMAN | ||
Type: | n/a | ||
Mol. Mass.: | 60128.79 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P49760 | ||
Residue: | 499 | ||
Sequence: |
| ||
BDBM317482 | |||
n/a | |||
Name | BDBM317482 | ||
Synonyms: | 4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide | US9623028, Compound 349 | ||
Type | Small organic molecule | ||
Emp. Form. | C33H39N7O5 | ||
Mol. Mass. | 613.7067 | ||
SMILES | CNC(=O)c1ccc(cc1)-c1c[nH]c2nc(Nc3ccc(cc3OC)C(=O)NC3CN(C)C3)nc(OC3CC[C@@](C)(O)CC3)c12 |r,wU:39.43,wD:39.42,(6.47,11.4,;6.08,9.92,;4.59,9.52,;3.5,10.61,;4.19,8.03,;5.28,6.94,;4.88,5.45,;3.39,5.06,;2.3,6.15,;2.7,7.63,;2.99,3.57,;3.9,2.32,;2.99,1.08,;1.53,1.55,;.19,.78,;-1.14,1.55,;-2.47,.78,;-2.47,-.76,;-1.14,-1.53,;-1.14,-3.07,;-2.47,-3.84,;-3.81,-3.07,;-3.81,-1.53,;-5.14,-.76,;-6.47,-1.53,;-2.47,-5.38,;-1.14,-6.15,;-3.81,-6.15,;-3.81,-7.69,;-4.9,-8.78,;-3.81,-9.86,;-3.81,-11.4,;-2.72,-8.78,;-1.14,3.09,;.19,3.86,;.19,5.4,;-1.14,6.17,;-2.47,5.4,;-3.81,6.17,;-3.81,7.71,;-3.81,9.25,;-5.14,6.94,;-2.47,8.48,;-1.14,7.71,;1.53,3.09,)| | ||
Structure |